Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ÀûÀÀÁõº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1529839
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,311,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,708,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,502,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 23¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß CAGR 8.58%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. R&D Ȱµ¿ÀÇ ¾Æ¿ô¼Ò½Ì Áõ°¡, ÷´Ü ÀǾàǰ¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä, CROÀÇ ±¹Á¦ Ç¥ÁØ µµÀÔ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

¶ÇÇÑ Æ¯Çã ¸¸·á·Î ÀÎÇÑ °æÀï Áõ°¡, Á¦³×¸¯ ÀǾàǰÀÇ ±Þ°ÝÇÑ ¼ºÀå, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ µµÀÔÀ¸·Î ÀÎÇÑ ¾Ð·ÂÀº Á¦¾à»çµéÀÌ CROÀÇ µµ¿òÀ» ¿äûÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ Á¾¾çÇÐ ±â¹Ý ¹ÙÀÌ¿À CRO »ê¾÷Àº ¿¹Ãø ±â°£ Áß À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ÁøÃâ±â¾÷ÀÇ Ã¤Åà ¹× Ä¿¹Â´ÏÄÉÀ̼ÇÀ» À§ÇÑ ¸ð¹ÙÀÏ Áö¿ø Çõ½Å, À¥ ±â¹Ý »ý¸í°úÇÐ ½ÇÇè½Ç, ÀÏ»óÀûÀÎ Å×½ºÆ®¸¦ ¼öÇàÇϱâ À§ÇÑ ·Îº¿ ½ÇÇè½Ç°ú °°Àº ±â¼ú ¹ßÀüÀº ½ÃÀåÀÇ ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¼¼°è Â÷¿ø¿¡¼­ »õ·Î¿î ½ÃÀå¿¡ ÁøÃâÇϰíÀÚ ÇÏ´Â ½ºÆù¼­ ¹× Á¦¾à»ç¿¡°Ô ¾Æ¿ô¼Ò½ÌÀº ÇϳªÀÇ ÇØ°áÃ¥ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. È­ÀÌÀÚ¿Í ±Û¶ô¼Ò ½º¹Ì½ºÅ¬¶óÀΰú °°Àº ´ëÇü Á¦¾à ȸ»ç´Â ÇöÁö CMO ¹× CRO¿Í Çù·ÂÇÏ¿© ¿Ü±¹°è ±â¾÷ÀÌ ½ÅÈï ±¹°¡¿¡¼­ ¸¶ÄÉÆÃ, ±ÔÁ¦ ¹× Á¦Á¶ ¸ñÇ¥¸¦ ´Þ¼º ÇÒ ¼ö ÀÖµµ·Ï ¼º°øÀûÀ¸·Î Çù·ÂÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¾÷°è³» ÇÕº´°ú Á¦ÈÞ Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ½ÃÀåÀ» È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 1¿ù, ºÐ¼® ¼Ö·ç¼Ç ±â¾÷ Bruker´Â ÀüÀÓ»ó Ȱµ¿ ¿ª·®À» È®´ëÇϱâ À§ÇØ ½ºÀ§½º¿¡ º»»ç¸¦ µÐ ÀüÀÓ»ó CRO ¹ÙÀÌ¿ÀÁ¦³×½Ã½º(Biogenesis)¸¦ ÀμöÇß½À´Ï´Ù.

Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå : ÀûÀÀÁõº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå Á¾¾çÇÐ ±â¹Ý In-vivo CRO ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.37 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies to seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope

Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis

Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis

Chapter 6. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â